Abstract. hMLH1 is involved in DNA mismatch repair and its defects cause hereditary non-polyposis colorectal cancer (HNPCC) as well as other types of cancer. A defective DNA mismatch repair system results in genetic instability, also referred to as microsatellite instability (MSI), which is a good indicator of HNPCC. Using in silico analysis of oligocapping cDNA sequences, we initially identified a splicing (variant type 2) whose second exon is 5 bp shorter than that of a genuine hMLH1 transcript (variant type 1) and a transcript using alternative promoter (variant type 3) whose transcription starts about 300 bases downstream of variant type 1. We then compared the expression level of variant types 1 and 3 among six colorectal cancer cell lines using real-time PCR. As a result, we found that the cell lines that completely suppress the expression of variant type 1 by hypermethylation expressed variant type 3 to a certain extent. This result suggests that the expression of variant types 1 and 3 did not completely follow the same transcription mechanism. We also found that the cell lines showing MSI to be positive either expressed variant type 3 more than type 1 or expressed only variant type 3. These results showed the potential applicability of mRNA expression analysis to molecular diagnostic tests of MSIpositive cancer types.
Introduction
The expressional and translational diversity of mRNAs or proteins from each single gene are mainly controlled by alternative splicing or use of alternative promoters in the mRNA transcription and RNA processing stages (1, 2) . Alternative splicing is a significant mechanism for modulating the expression of genes and enables a single gene to increase its coding pattern, producing splicing variants and enabling the synthesis of several structurally and functionally distinct protein isoforms (1) . Alternative promoters are alternative regions from which transcripts of genes originate. The existence of alternative promoters means that a gene has several transcriptional start sites (TSSs). Consequently, several types of transcriptional products that differ in their 5' terminal are produced (2) . Recent research on 1,780,295 types of 5'-end cDNA sequences obtained from oligo-capping cDNA clones, showed that ~52% of genes assigned to the RefSeq database (http://ncbi.nih.gov/RefSeq/) were found to be under the influence of alternative promoters. Among them, there is an average of 3.1 alternative promoters per gene (3) . These phenomena have been found to be associated with a variety of diseases, including cancer (4, 5) .
DNA mismatch repair system is the primary pathway for correcting replication errors. In >90% of hereditary nonpolyposis colorectal cancer (HNPCC) syndrome cases, the representative disease of familial colorectal cancer and a defective DNA mismatch repair system resulted in genetic instability, also referred to as microsatellite instability (MSI) (6, 7) . Microsatellites are short repetitive sequences: two mononucleotide repeats (BAT25 and BAT26) and three dinucleotide repeats (D2S123, D5S346 and D17S250). These five nucleotide repeats are called microsatellite markers, and their instabilities indicate the number by which the repetitive sequences decrease or increase (8) . MSI is easily observed using PCR, which detects microsatellite markers (9) . A total of ~85% of HNPCC patients exhibit MSI, and this proportion is even higher in mutation-positive families (10) . MSI is also found in 10-15% of sporadic colorectal tumor patients (10) .
The genetic diagnosis of cancer is generally based on the mutation analysis of responsible gene(s). Unlike the APC gene, which is responsible for familial adenomatous polyposis syndrome (11) , five mismatch repair genes (hMLH1, hMSH2, hMPS1, hPMS2 and hMSH6) have been identified for HNPCC (10) . Of the five genes, hMLH1 (12, 13) and hMSH2 (14) are the most extensively analyzed genes associated with HNPCC syndrome. hMLH1, for example, causes HNPCC by a nonsense mutation of codon 252 in exon 9 (TCA-TAA, Ser-Stop) (13) or by a lack of hMLH1 mRNA exons 6 and 7 ONCOLOGY REPORTS 22: 265-271, 2009 265 Differences in expression between transcripts using alternative promoters of hMLH1 gene and their correlation with microsatellite instability (15) . In addition, loss of hMLH1 expression due to hypermethylation of the hMLH1 promoter region leads to colorectal cancer by means of MSI (16) . In the present study, using in silico analysis of oligocapping cDNA sequences, we identified a new transcript using an alternative promoter which starts ~300 bases downstream of the genuine hMLH1 TSS. Using real-time PCR on three types of colorectal cancer cell lines, which have distinctive characteristics regarding hypermethylation and MSI, we compared the expression levels of transcripts derived from each promoter. We also evaluated the potential applicability of mRNA expression analysis to molecular diagnostic tests of MSI-positive cancer types.
Materials and methods
Cell lines and culture. SW48 (colorectal adenocarcinoma), RKO and HCT116 (colorectal carcinoma) were obtained from the American Tissue Culture Collection (Manassas, VA). LoVo, COLO320 DM and COLO201 (colorectal adenocarcinoma) were obtained from the Human Science Research Resources Bank (Osaka, Japan). Cells were cultured in advanced DMEM (Invitrogen, Carlsbad, CA) and supplemented with 10% fetal bovine serum (Invitrogen) and antibiotics. Cell cultures were maintained in a humidified incubator at 37˚C under 5% CO 2 .
Acquisition of hMLH1-related genomic and cDNA alignments. 5'-end human cDNA sequences from full-length cDNA libraries derived from 164 kinds of human tissues, and cultured cells were isolated from the deposition sequences described in the literature (3). These cDNA libraries were constructed using oligo-capping methods (17) . Using the RefSeq sequence of hMLH1 (NM_000249) as a query, a computer-based homology search using the blastn program from the BLAST package (18) was applied to these sequences that were multi-FASTA formatted. Sequences with a high degree of similarity (blast E value <10 -10 ) were selected as hMLH1-related cDNAs. To obtain the corresponding alignments, the bl2seq program from the BLAST package was carried out between the genomic sequences in the hMLH1 region dissected from the human genome chromosome 3 sequence (NT_022517) and each sequence of the hMLH1-related cDNAs described above. Subsequently, the alignments that were correctly aligned ahead of the second exonic region of the hMLH1 RefSeq (http://www.ncbi.nlm.nih.gov/RefSeq/) sequence (NM_000249) and those that also closely matched (an identity of 98% or more) were selected from the whole set of alignments.
Analysis of hMLH1 mRNA expression. hMLH1 gene expression was measured by TaqMan-based real-time reverse transcriptase-PCR. Total RNA was extracted from cell lines using a DNeasy tissue kit (Qiagen, Hilden, Germany). Total RNA (1.0 μg) was reverse-transcribed with 2.0 μl of oligodT (20) primer (50 μM), 4.0 μl of dNTP mix (5 mM), 8.0 μl of 5X first-strand buffer, 2.0 μl of DTT (100 mM), 2.0 μl of DEPC-treated water, and SuperScript™ III reverse transcriptase (Invitrogen) with a total volume of 40 μl according to the manufacturer's instructions.
After reverse transcription, real-time PCR was conducted in an ABI PRISM 7900 HT (Applied Biosystems, Foster City, CA) to determine the expression levels of variant types 1 and 3 with a final reaction mixture of 1.0 μl of RT-products, 10 μl of TaqMan Universal Mastermix, 3.5 μl of forward primer (F, 5.0 μM), 3.5 μl of reverse primer (R, 5.0 μM), 3.5 μl of TaqMan probe (5.0 μM) and water with a total volume of 20 μl using a 384-well optical tray. PCR conditions were: initial denaturing at 95˚C for 10 min, 40 cycles of denaturing at 95˚C for 15 sec and annealing/extension at 60˚C for 1 min. The forward and reverse primer for variant type 1 and probe sequences were: 5' to 3', F: CAGCGGCCAGCTAATGCTAT, R: CCATTGTCTTGATCTGAATCAACTTC, and Probe: FAM-CAAGTATTCAAGTGATTGTTAAAGAGGGAG GCC-TAMRA (Applied Biosystems). The forward primer sequence for variant type 3 was 5' to 3', F: GGGTTGTTT GGAGTTTTAGATGCA. The reverse primer and the TaqMan probe for variant type 3 were the same as those for variant type 1. The fluorescence emitted by the reporter dye was detected in real time, and the threshold cycle (Ct) of each sample was recorded as a quantitative measure of the amount of PCR product in the sample.
The standard curve based on the Ct was generated using cDNA from the cell line COLO320 DM, which expresses high-level hMLH1 mRNA. PCR products were prepared before the real-time PCR using cDNA from COLO320 DM as a template with a final mixture of 2.0 μl of RT-products, 5.0 μl of 10X PCR buffer, 4.0 μl of dNTP mix (2.5 mM), 3.5 μl of forward primer (5.0 μM), 3.5 μl of reverse primer (5.0 μM), 0.25 μl of ExTaq (Takara Bio Inc., Japan) and water with a total volume of 50 μl. PCR conditions were: initial denaturing at 95˚C for 10 min, 35 cycles of denaturing at 95˚C for 30 sec, annealing at 63˚C for 1 min and extension at 72˚C for 1 min, as well as a final extension at 72˚C for 10 min. The forward and reverse primer sequences for a standard curve of variant type 1 were: 5' to 3', F: CTGGACGAGACA GTGGTGAAC and R: ATACTGGCTAAATCCTCAAAGG ACTG. The forward primer sequence for the standard curve of variant type 3 was 5' to 3', F: TTTCTTTACCGCTCTCC CCCG. The reverse primer was the same as that for variant type 1. After serial dilution, the PCR products were measured by real-time PCR and the Ct was determined. The Ct is the fractional cycle number at which the fluorescence generated by the reporter dye exceeds a fixed level above the baseline.
Results
Identification of an alternative promoter of the hMLH1 gene using in silico analysis of oligo-capping cDNA sequences. The human MLH1 (hMLH1, human mutL homologue 1) gene is an E. coli homologue of the DNA mismatch repair gene mutL and is recognized as a gene locus at which high frequency mutations are observed on HNPCC. RefSeq mRNA sequence of hMLH1 consists of 19 exons.
Using in silico analysis (see Materials and methods), we obtained 187 hMLH1-related cDNA sequences which were assumed to have TSSs. We classified these sequences into variant types 1, 2 and 3. The first three exons of the 19 exonic regions, variant types 1, 2 and 3, are shown in Fig. 1(a)  (12,19) . The hMLH1 RefSeq sequence belongs to variant type 1. Variant type 2 has almost the same exonic structure, but the 5'-end of the second exon is 5 bp shorter than that of variant type 1. We assumed that type 2 is a splicing variant. Variant type 3 has the same sequence as exons 2 and 3 of variant type 1, but the TSSs are located ~300 bp downstream of those of variant types 1 and 2 (Fig. 2) . Of the 187 hMLH1-related cDNA sequences, 141 belonged to variant type 1, 14 belonged to variant type 2 and 32 belonged to variant type 3. The corresponding percentages of the total were 75, 7.5 and 17%, respectively. Even though variant type 1 is a significant transcript, variant types 2 and 3 are also transcribed to a large extent. Accession numbers of the hMLH1-related cDNA sequences in the public DNA sequence databanks are listed in Table I . The TSSs, whose sequences are shown in Fig. 2 , were scattered over a relatively wide range for each variant type. As the promoter region of the hMLH1 gene lacked the canonical TATA box, this is not unusual (20) .
Expressional change of variant types 1 and 3 of hMLH1 gene.
A recent study showed that the range over which the TSSs are scattered is on average 62 bp, with a standard deviation of 20 bp. Moreover, it was assumed that the possibility of TSSs belonging to a single cluster scattered over a range of >500 bp would be very low (3). It would be interesting to know whether or not variant types 1 and 3 are subject to different expressional (or alternative promoter usage) regulations since the TSS intervals of these genes are only ~300 bp.
We examined the dependence of the expression on the position of the TSS using colorectal cancer cell lines. We used three types of cell lines based on the results in the literature (Table II) (13, 14) . COLO201 and COLO320 DM were methylation-and MSI-free. RKO and SW48 were methylation-and MSI-positive, while HCT116 and LoVo were methylation-free but MSI-positive. Since preliminary results showed that, under the present experimental conditions, Table I . DNA databank accession numbers and variant type. AU131219  DA031179  DA050403  DA110166  DB243737  DA707133  DA173423  DA262636  AU127758  DA716690  DA125431  DB040429  DA909925  AU128432  DA501808  DA819642  DA619769  DA472218  DA043349  DA880601  DA453337  DA555707  DA881017  DA356018  DA024420  DA983131  DA695612  DA475144  DA055019  DB092229  DB000482  DA919830  DA953555  DA702671  DB272759  DA762271  DA209147  DA555444  DA546685  DA751926  DA023897  DA701340  DB090691  DA503831  DA914770  DA880449  DA349545  DA207023  DA486475  DB200826  DA556556  DA494857  DA472331  DA033654  DB008432  DA659014  DA932049  DA304561  DB274178  DB252001  DA609156  DA305360  DA970996  DA599881  DA426942  DA658037  DA659112  DB120181  DA752464  DA013759  DA308229  DA503294  DA555173  DA624450  DB270772  DA666173  DB014982  DB266774  DA729732  DB011897  DA479521  DA489729  DB269584  DA631956  DA958303  DA877866  DA972163  DA582565  DA524635  DA476333  DA559708  DA518707  DA952805  DB055056  DA563477  DA287218  DA447945  AU280370  DA913772  DA698928  DA783187  DA887994  DA554567  DA765712  DA952842  DA374168  DA619525  DB246315  DA884873  DA997466  DA690019  DA656699  DA350100  DA201970  DA478068  DA106361  DA794400  DA874359  DA738557  DA592612  DA915432  DA577087  DA503277  DA712069  DA287058  DA478450  DA086654  DA004869  DA790495  DA926525  DA937827  DA493353  DB040297  DB089707  DA660079  DA510241  DA050020  DA814813  DA650335  DA911985  DA348650  - DA385243  DA868597  DA815001  DA070867  DB139980  DB287548  DB157098  DB012065  DB114802  DB018927  DA866298  DA352218  DA506267  DB252510  - AU127122  DA517219  DB204422  DA814707  DA927898  DA430514  DA922309  DB012054  DA935122  DA343206  DA930241  DA166268  DA921733  DA303777  DA476068  DA296090  DB253300  DA156778  DA566031  DA748219  DA963961  DA664790  DA580525  DB259565  DA073874  DA749519  DA750838  DA582466  DA172498  DA275297  DA821467  DA955738  - 
----------------------------------------------------------------------------------------------------Type 2 Total 14 -----------------------------------------------------------------------------------------------------

----------------------------------------------------------------------------------------------------Type 3 Total 32 -----------------------------------------------------------------------------------------------------
----------------------------------------------------------------------------------------------------
a Types 1, 2 and 3 represent 75, 7.4 and 17.6% of the total, respectively. 
-----------------------------------------------------------------------------------------------------
----------------------------------------------------------------------------------------------------- COLO201 COLO320 DM RKO SW48 HCT116 LoVo ----------------------------------------------------------------------------------------------------- Expression 1>3 1>3 1(-), 3(+) 1(-), 3(+) 1<3 1<3 M S I - - + + + + Methylation - - + + - - --
---------------------------------------------------------------------------------------------------
a Data for expression were obtained from experimental results (Fig. 3) . Data for MSI and methylation status are found in the literature (22) , while the MSI status was determined by an analysis of the BAT25 and BAT26 loci. Methylation status of the hMLH1 promoter was investigated between bases -711 and +15 in each cell line. 1<3 means the copy number of variant type 3 is higher than that of type 1, and 1>3 the opposite. 1(-) means the expression of variant type 1 was negative and 3(+) means the expression of variant type 3 was positive.
-- --------------------------------------------------------------------------------------------------- the expression of variant type 2 was negligibly small compared with that of variant type 1, we examined the difference between variant types 1 and 3 of hMLH1 whose 5' most extended sequences are shown in Fig. 3 .
As a result, we categorized the cell lines into three groups in terms of the expressional change of variant types 1 and 3 by quantitative real-time PCR (Fig. 4) . Thus, the expressional patterns of variant type 3, whose existence was shown in the present investigation for the first time, were completely different from those of variant type 1. In the COLO201 and COLO320 DM group, variant type 1 expressed at a higher rate than variant type 3. In contrast, even though the expression of variant type 1 of RKO and SW48 was completely suppressed by methylation in the promoter region, their expression of variant type 3 was observed. In addition, in the HCT116 and LoVo group, although the expression of variant type 1 was shown to be positive by qualitative real-time PCR (13), it was down-regulated compared with the cases of COLO201 and COLO320 DM, while the expression of variant type 3 showed almost no change. In other words, MSI-positive cell lines expressed variant type 3 more than variant type 1, including a complete suppression of variant type 1 cell lines RKO and SW48.
Discussion
Role of variant type 3 of hMLH1 gene. The domain structure of the hMLH1 protein is shown in Fig. 1(b) (12,21) . is in the first exon of variant type 1. As the second ATG in that reading frame is also in the first exon of variant type 1, the most plausible coding sequence for variant types 2 and 3 starts from the third ATG of the genuine hMLH1 coding sequence, which starts 723 bp downstream of the first ATG. This causes a 241 amino acid truncation at the N-terminal end of the hMLH1 protein. The predicted protein sequence coded by variant type 3 mRNA lacks most of its ATPase domain including conserved loops L45 that are thought to contain the MutS-MutL interaction interface (21) . In spite of this, we found that variant type 3 is transcribed to a large extent.
Although the mechanism for variant type 3 expression and the specific effect of the expression on carcinogenesis are unknown, we considered from these results that the role of variant type 3 has at least three possible roles to play. First, variant type 3 is 'junk'. Second, the translatable protein from variant type 3 lacks ~30% of the amino acids at the N-terminal end of the intact hMLH1 protein. This results in the loss of most of the ATPase domain whose original function was that of mismatch repair, and thus exhibits the biological functions of a shorter protein. Third, it is a so-called functional non-coding RNA. Recently, Martianov et al reported that non-coding RNA from a minor promoter, which is different from a major one (also known as a normal promoter) for complete mRNA transcription, causes transcriptional repression (22) . The first case seems to be a waste of energy and biologically meaningless. However, it is plausible that a certain amount of 'junk' mRNAs are transcribed as many splicing variants and alternative promoters have been identified (1, 2) . If the transcript of variant type 3 codes a functional shorter protein or is a functional non-coding RNA, it can affect the expression of hMLH1, resulting in MSI and carcinogenesis. It may also have a novel function. However, revealing the role of variant types 2 and 3 requires further investigation.
Expressional regulation of variant types 1 and 3 of hMLH1.
Human MSH2 (hMSH2, human MutS homologue 2) is a significant responsible gene that induces MSI as well as hMLH1. Germ-line mutations or genomic deletions of hMSH2 or hMLH1 cause HNPCC syndrome (23) (24) (25) . One group that measured protein expression by immunohistochemistry has reported that ~90% of families that express only hMLH1 (variant type 1) or hMSH2 proteins are MSI-positive, while families expressing hMLH1 and hMSH2 are microsatellite stable (26) .
We showed that LoVo and HCT116 express variant type 3 more than variant type 1 and they show MSI to be positive. HCT116 has a mutation in exon 9 of hMLH1 that introduces a translational stop codon (TCA-TAA), and LoVo has truncated RNA (exon 4-8 deletion) for the hMSH2 gene (13) . These mutations produce defective hMLH1 and hMSH2 proteins, respectively, which probably causes MSI in each cell line. Accordingly, it is notable that defects in the hMLH1 and hMSH2 proteins down-regulate the expression of the intact mRNA of the hMLH1. There is also a common mechanism for expressing the two mRNAs that require the existence of both intact proteins. Using a publicly available database, we investigated whether or not there is a correlation between the expression of hMLH1 and hMSH2 mRNA. The Genomics Institute of the Novartis Research Foundation, has designed custom arrays that interrogate the expression of the vast majority of protein-encoding human and mouse genes and has used them to profile a panel of 79 human and 61 mouse tissues, and the results are available at http://symatlas. gnf.org/SymAtlas/ (27) . The correlation analysis on that site showed a close correlation between hMLH1 and hMSH2 gene expression. The array system used the array analysis protocols gcRMA (28) and Affymetrix's default MAS5.0 (29), for which correlation data was provided. According to these analyses, hMSH2 was positioned 8th by gcRMA and 14th by MAS5.0 to hMLH1 for >20,000 target sequences and hMLH1 was positioned 6th by gcRMA and 11th by MAS5.0 to hMSH2 (data not shown). Furthermore, among the genes whose expression correlates with the hMSH2 gene, there is only one common gene that ranks ahead of hMLH1. Results obtained from the two analysis methods also showed that among the genes whose expression correlates with the hMLH1 gene, there is also only one common gene that ranks ahead of hMSH2. This shows a close correlation between the expression of the two genes. Thus, there may be a common mechanism to transcribe them in the same manner as that regulated by the two proteins.
Applicability of expressional changes between variant types to cancer diagnosis.
Colorectal cancer is one of the most serious malignant tumors that cause mortality, but is curable if it is surgically treated in the early stages. The hemoccult fecal blood test is currently used for mass screening, but it is non-specific and not sufficiently sensitive to detect early stage colorectal cancer (30) . Screening methods for colorectal cancer that make use of the detection of DNA mutations in the cancer-related genes have been reported. Among these, Matsumura's group reported a method that isolates colonocytes from several grams of feces, detects DNA mutations for APC, K-ras and p53 genes, and analyzes MSI (31) . These methods mainly depend on the detection of the mutation of the multi-step process model-related genes of colorectal cancer, and attained sensitivities are at most ~70%. Research indicates that 10-15% of sporadic colorectal tumors show MSI (10) . Thus, the effective detection of MSI or defects of mismatch repair will improve those sensitivities. We propose a novel method that measures the expression ratio of variant types 1-3 of the hMLH1 gene to improve sensitivity. Even though a method described in the literature (10) uses BAT26 analysis, BAT26 alone is not sufficient to detect MSI or the defection of mismatch repair gene(s) as a whole. MSI is a result of a mismatch repair defect, making the detection of the latter more direct and therefore more effective. Matsumura's group also demonstrated recovery mRNA from exfoliated colonocytes isolated from feces (32) . Consequently, gene expression measurement in a single cell has become feasible (33) . Quantitative measurement has always been considered to have difficulties in maintaining quantitativeness, but the proposed method has resolved this issue by adding an ideal inner standard: variant type 3. We anticipate that the present findings will contribute to the development of an early stage method of screening for colorectal cancer.
